CMC development of peptides - A case study

An effective CMC strategy for any peptide API should include risk mitigation approaches suitable for the intended clinical or commercial phase. The development and technology transfer of a Peptide API process (e.g. Lanreotide) will be presented as a case study in tailoring projects to specific regulatory routes or applications. Presented by Jyothi Thundimadathil, Associate Director, CMC Watch the full video here, find it at the "CMC development" live area of Bachem360: https://hub.bachem.com/en-GB/bachem-360/live-area -------------------------------------------------------------------------------------------------------------------- About Bachem: Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has over 50 years of experience and expertise, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services. Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange. Learn more about our products and services at https://www.bachem.com/​